Efficacy News and Research

RSS

Revlimid clinical data in newly diagnosed multiple myeloma presented

Celgene Corporation announced today that data evaluating clinical results on Revlimid (lenalidomide) as a new therapeutic approach for patients with newly diagnosed multiple myeloma (MM) was presented at the American Society of Hematology 46th Annual Meeting in San Diego.

7 Dec 2004

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

Escalating costs and lengthy clinical trials are major concerns for researchers attempting to boost productivity and efficiency in the field of drug discovery. Biomarkers are emerging as the solution to these problems with their ability to reduce drug development costs and time.

7 Dec 2004

New insight into anticoagulation therapies

Anticoagulation therapies, or treatments that reduce the amount of clotting factors in the blood, are quite common and used for a variety of reasons.

6 Dec 2004

New advances in sickle cell disease

Excruciating pain episodes, recurrent pneumonias, strokes, severe infections, chronic hemolytic anemia, and secondary pulmonary hypertension are common complications of sickle cell disease, a life-threatening inherited defect in blood that causes normally disc-shaped red blood cells to take on a sickle shape.

6 Dec 2004

Electrochemical DNA chip that is able to detect DNA at very low concentrations

Toshiba Corporation has announced the development of a highly sensitive electrochemical DNA chip that is able to detect DNA at very low concentrations, a capability that will support advances in gene detection and analysis for individual treatment regimes, and the monitoring of healthy individuals for any predisposition to certain diseases.

6 Dec 2004

Review findings released on the safety of antidepressants (SSRI's)

The Medicines and Healthcare products Regulatory Agency (MHRA) issued new advice to patients and doctors about the group of antidepressants known as SSRI's, today.

6 Dec 2004

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

Results from a clinical trial presented at the American Society of Hematology 46th Annual Meeting and Exposition (ASH) demonstrated that Zevalin (ibritumomab tiuxetan), administered as a first-line therapy, induced a 100 percent response rate in a small population of patients with low-grate follicular lymphoma (FL).

6 Dec 2004

New drug can successfully treat patients who have become resistant to Gleevec

A team of prominent researchers led by Charles Sawyers, M.D. and Moshe Talpaz, M.D., presented compelling clinical findings today showing that a new drug, BMS-354825, can successfully treat patients who have become resistant to Gleevec (the frontline therapy for chronic myelogenous leukemia, CML).

5 Dec 2004

Researchers step closer to cure for common childhood cancer

Acute lymphoblastic leukemia (ALL) is a malignant disease caused by the abnormal growth and development of white blood cells (WBC) in the bone marrow and blood. ALL is the most common cancer occurring in children with an annual rate of approximately 30 to 40 new cases per million.

5 Dec 2004

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

Telik, Inc. reported positive interim data from a Phase 2 trial of its Telintra (TLK199) drug candidate in myelodysplastic syndrome (MDS). The data were reported in two presentations at the annual meeting of the American Society of Hematology in San Diego.

5 Dec 2004

A new treatment for patients with chronic myeloid leukemia

A new treatment for patients with chronic myeloid leukemia (CML) -- a disorder marked by an overproduction of white blood cells -- yields positive results in those who have relapsed on imatinib, the standard treatment for the disease, according to a Phase I study to be presented today at the 46th Annual Meeting of the American Society of Hematology (ASH).

5 Dec 2004

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

At the 46th Annual Meeting of the American Society of Hematology (ASH) preliminary data were presented from a phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia (MDS).

5 Dec 2004

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Guidelines needed for the use of androgens for women with sexual dysfunction

The Endocrine Society, which represents more than 12,000 endocrinologists who are specially trained to diagnose, treat and conduct basic and clinical research on complex hormonal disorders, has called for new clinical guidelines on the use of androgens in women/female sexual dysfunction.

3 Dec 2004

Smoking habits during pregnancy may cause genetic instability in the foetus

The Spanish Pediatrics Association has recently awarded the Pediatrics laboratory at the University of Navarre for a research into tobacco and foetal genetic instability.

2 Dec 2004

Higher incidence of rejection following early steroid withdrawal

A new study on early steroid withdrawal following liver transplantation found that there was a higher incidence of rejection and a lower incidence of glucose intolerance necessitating treatment for diabetes.

1 Dec 2004

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

The two medicines (which are used in the treatment of AIDS) had been delisted by WHO in May this year due to non-compliance with international standards at the contract research organizations (CROs) hired by Cipla to conduct bioequivalence tests on the products.

30 Nov 2004

Adding a commonly used dietary supplement to antidepressants may improve treatment

Massachusetts General Hospital (MGH) researchers have found that adding the nutritional supplement SAMe to a standard antidepressant may be helpful to patients who have not responded to single-drug treatment for clinical depression.

30 Nov 2004

Viral Genetics announces effects of VGV-1 in antiretroviral non-responding HIV infections

Viral Genetics announced today that the results of a clinical trial of its investigational therapy for HIV infection, VGV-1, were recently published in a peer reviewed journal, HIV & AIDS Review.

29 Nov 2004

Drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria

Results of a randomised trial from Uganda in this week’s issue of THE LANCET suggest that the drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria in terms of efficacy and cost-effectiveness in this region.

29 Nov 2004

Efficacy News and Research

Revlimid clinical data in newly diagnosed multiple myeloma presented

Escalating costs and lengthy clinical trials are major concerns for researchers in the field of drug discovery

New insight into anticoagulation therapies

New advances in sickle cell disease

Electrochemical DNA chip that is able to detect DNA at very low concentrations

Review findings released on the safety of antidepressants (SSRI's)

Zevalin highly effective in first-line treatment of low-grade follicular lymphoma

New drug can successfully treat patients who have become resistant to Gleevec

Researchers step closer to cure for common childhood cancer

Positive results from phase 2 trial of Telintra, drug candidate in myelodysplastic syndrome

A new treatment for patients with chronic myeloid leukemia

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Single dose phase I data on CG53135 for the prevention of oral mucositis

Guidelines needed for the use of androgens for women with sexual dysfunction

Smoking habits during pregnancy may cause genetic instability in the foetus

Higher incidence of rejection following early steroid withdrawal

World Health Organization is reinstating two antiretrovirals manufactured by Cipla Ltd

Adding a commonly used dietary supplement to antidepressants may improve treatment

Viral Genetics announces effects of VGV-1 in antiretroviral non-responding HIV infections

Drug combination of amodiaquine and sulfadoxinepyrimethamine might offer the optimal treatment for malaria

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News